Literature DB >> 12692252

Hepatitis B virus-mediated changes of apolipoprotein mRNA abundance in cultured hepatoma cells.

Pamela A Norton1, Qiaoke Gong, Anand S Mehta, Xuanyong Lu, Timothy M Block.   

Abstract

An inverse correlation between hepatitis B virus (HBV) and steady-state levels of apolipoprotein AI and CIII mRNAs was observed in two hepatoma cell lines. Analysis of a third line containing an inducible viral genome implicated viral pregenomic RNA in apolipoprotein mRNA reduction. We conclude that HBV alters infected cells despite the absence of overt cytopathogenicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692252      PMCID: PMC153946          DOI: 10.1128/jvi.77.9.5503-5506.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

Review 1.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

2.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 3.  Changes in the concentration and composition of plasma lipoproteins during the acute phase response.

Authors:  Yvon A Carpentier; Olivier Scruel
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2002-03       Impact factor: 4.294

4.  Serum lipids and lipoproteins in chronic liver disease.

Authors:  J Fehér; L Romics; L Jakab; E Fehér; I Szilvási; G Papp
Journal:  Acta Med Acad Sci Hung       Date:  1976

Review 5.  Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo.

Authors:  V I Zannis; H Y Kan; A Kritis; E E Zanni; D Kardassis
Journal:  Curr Opin Lipidol       Date:  2001-04       Impact factor: 4.776

Review 6.  Characterization of lipoproteins produced by the human liver cell line, Hep G2, under defined conditions.

Authors:  R N Thrift; T M Forte; B E Cahoon; V G Shore
Journal:  J Lipid Res       Date:  1986-03       Impact factor: 5.922

7.  Apolipoproteins A-I, A-II and B in chronic active hepatitis and in liver cirrhotic patients.

Authors:  C Cordova; A Musca; F Violi; C Alessandri; L Iuliano
Journal:  Clin Chim Acta       Date:  1984-02-14       Impact factor: 3.786

8.  Serum total lipids, lipoprotein cholesterol, and apolipoprotein A in acute viral hepatitis and chronic liver disease.

Authors:  C Vergani; G Trovato; A Delù; M Pietrogrande; N Dioguardi
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

9.  Serum apoprotein A-I and A-II levels in liver diseases and cholestasis.

Authors:  S Fujii; S Koga; T Shono; K Yamamoto; H Ibayashi
Journal:  Clin Chim Acta       Date:  1981-09       Impact factor: 3.786

10.  Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions.

Authors:  M A Sells; A Z Zelent; M Shvartsman; G Acs
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

View more
  11 in total

Review 1.  Association between hepatitis B and metabolic syndrome: Current state of the art.

Authors:  Peter Jarcuska; Sylvia Drazilova; Jan Fedacko; Daniel Pella; Martin Janicko
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Low plasma apolipoprotein A-I level is not a reliable marker of fibrosis in children with chronic hepatitis B.

Authors:  Mukadder-Ayse Selimoglu; Rasit-Vural Yagcl; Gül Yüce
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

3.  Identification of cellular genes showing differential expression associated with hepatitis B virus infection.

Authors:  Yasuo Fukuhara; Takeshi Suda; Makoto Kobayashi; Yasushi Tamura; Masato Igarashi; Nobuo Waguri; Hirokazu Kawai; Yutaka Aoyagi
Journal:  World J Hepatol       Date:  2012-04-27

4.  Association between chronic hepatitis B infection and metabolic syndrome.

Authors:  Xiaohui Zhao; Drishti Shah; Usha Sambamoorthi
Journal:  J Diabetes Metab Disord       Date:  2018-10-27

Review 5.  Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure.

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2021-04-23       Impact factor: 5.048

6.  HBV inhibits apoB production via the suppression of MTP expression.

Authors:  Fu-Bing Wang; Cheng-Liang Zhu; Xinghui Liu; Guo-Sheng Gao
Journal:  Lipids Health Dis       Date:  2011-11-11       Impact factor: 3.876

7.  Investigation into the effect of hepatitis B virus on apoliprotein A1 expression and its mechanism.

Authors:  Weichao Jiang; Lei Zheng; Qianqian Yang; Zhouying Huang; Xiaobei Wang
Journal:  Lipids Health Dis       Date:  2014-08-13       Impact factor: 3.876

8.  The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus.

Authors:  Yuanyuan Wang; Junli Hao; Xiaohong Liu; Hongxin Wang; Xin Zeng; Jing Yang; Lei Li; Xi Kuang; Tao Zhang
Journal:  Lipids Health Dis       Date:  2016-03-25       Impact factor: 3.876

9.  Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA.

Authors:  Chengliang Zhu; Hui Song; Bingzheng Shen; Long Wu; Fang Liu; Xinghui Liu
Journal:  Lipids Health Dis       Date:  2017-01-11       Impact factor: 3.876

10.  Proteomic profiling of HBV infected liver biopsies with different fibrotic stages.

Authors:  Seyma Katrinli; Kamil Ozdil; Abdurrahman Sahin; Oguzhan Ozturk; Gozde Kir; Ahmet Tarik Baykal; Emel Akgun; Omer Sinan Sarac; Mehmet Sokmen; H Levent Doğanay; Gizem Dinler Doğanay
Journal:  Proteome Sci       Date:  2017-04-20       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.